{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:56:39Z","timestamp":1668714999544},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Ferrer International, S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12888-017-1291-5","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T22:20:57Z","timestamp":1491344457000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder"],"prefix":"10.1186","volume":"17","author":[{"given":"L.","family":"San","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Oudovenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"1291_CR1","unstructured":"World Health Organization. Trastornos mentales. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs396\/es\/ ."},{"key":"1291_CR2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","volume":"17","author":"M Garriga","year":"2016","unstructured":"Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vazquez G, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17:86\u2013128.","journal-title":"World J Biol Psychiatry"},{"key":"1291_CR3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pra.0000398410.21374.7d","volume":"17","author":"CS Hankin","year":"2011","unstructured":"Hankin CS, Bronstone A, Koran LM. Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment. J Psychiatr Pract. 2011;17:170\u201385.","journal-title":"J Psychiatr Pract"},{"key":"1291_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5811\/westjem.2011.9.6863","volume":"13","author":"K Nordstrom","year":"2012","unstructured":"Nordstrom K, Zun L, Wilson M, Vs M, Ng AT, Bregman B, et al. Medical evaluation and triage of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA medical evaluation workgroup. West J Emerg Med. 2012;13:3\u201310.","journal-title":"West J Emerg Med"},{"issue":"5","key":"1291_CR5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1092852914000054","volume":"19","author":"L Citrome","year":"2014","unstructured":"Citrome L, Volavka J. The psychopharmacology of violence: making sensible decisions. CNS Spectr. 2014;19(5):411\u20138.","journal-title":"CNS Spectr"},{"key":"1291_CR6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.schres.2007.12.480","volume":"100","author":"CG Huber","year":"2008","unstructured":"Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, et al. Validation of a clinical global Impression scale for aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophr Res. 2008;100:342\u20138.","journal-title":"Schizophr Res"},{"key":"1291_CR7","first-page":"311","volume":"23","author":"X Jimenez","year":"2011","unstructured":"Jimenez X, Espila JL, Gallant J. Activation codes: past, present and future in Spain. Emergencies. 2011;23:311\u20138.","journal-title":"Emergencies"},{"key":"1291_CR8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.genhosppsych.2003.08.002","volume":"26","author":"MH Allen","year":"2004","unstructured":"Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry. 2004;26:42\u20139.","journal-title":"Gen Hosp Psychiatry"},{"key":"1291_CR9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.psiq.2015.04.002","volume":"22","author":"E Garrido Vi\u00f1ado","year":"2015","unstructured":"Garrido Vi\u00f1ado E, Lizano-D\u00edez I, Roset Ariss\u00f3 PN, et al. El coste econ\u00f3mico de los procedimientos de contenci\u00f3n mec\u00e1nica de origen psiqui\u00e1trico en Espa\u00f1a. Psiquiatr Biol\u00f3gica. 2015;22:12\u20136.","journal-title":"Psiquiatr Biol\u00f3gica"},{"key":"1291_CR10","first-page":"417","volume":"15","author":"M Rubio-Valera","year":"2015","unstructured":"Rubio-Valera M, Luciano JV, Ortiz JM, Slavador-Carulla L, Gracia A, Serrano-Blanco A. Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence. BMC Psychiatry. 2015;15:417.","journal-title":"BMC Psychiatry"},{"key":"1291_CR11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200565090-00003","volume":"65","author":"J Battaglia","year":"2005","unstructured":"Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65:1207\u201322.","journal-title":"Drugs"},{"key":"1291_CR12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00023210-200216040-00002","volume":"16","author":"GW Currier","year":"2002","unstructured":"Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs. 2002;16:219\u201328.","journal-title":"CNS Drugs"},{"issue":"4 Suppl","key":"1291_CR13","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jemermed.2004.09.001","volume":"27","author":"GW Currier","year":"2004","unstructured":"Currier GW, Allen MH, Bunney EB, Daniel DG, Francis A, Jagoda A, et al. Standard therapies for acute agitation. J Emerg Med. 2004;27(4 Suppl):S9\u2013S12.","journal-title":"J Emerg Med"},{"key":"1291_CR14","unstructured":"Abilify\u00ae 7.5 mg\/mL solution for injection. Summary of Product Characteristics. Otsuka Pharmaceutical Europe Ltd. 4 June 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000471\/WC500020170.pdf ."},{"key":"1291_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-5618.2011.00975.x","volume":"14","author":"J Kwentus","year":"2012","unstructured":"Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14:31\u201340.","journal-title":"Bipolar Disord"},{"key":"1291_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1192\/bjp.bp.110.081513","volume":"198","author":"MD Lesem","year":"2011","unstructured":"Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of loxapine. Br J Psychiatry. 2011;198:51\u20138.","journal-title":"Br J Psychiatry"},{"key":"1291_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12991-015-0053-3","volume":"14","author":"D Popovic","year":"2015","unstructured":"Popovic D, Nuss P, Vieta E. Revisiting loxapine: a systematic review. Ann General Psychiatry. 2015;14:15.","journal-title":"Ann General Psychiatry"},{"key":"1291_CR18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hup.2535","volume":"31","author":"Y Dundar","year":"2016","unstructured":"Dundar Y, Greenhalgh J, Richardson M, Dwan K. Pharmacological treatment of acute agitation associated with psychotic bipolar disorder: a systematic review and meta-analysis. Hum Psychopharmacol. 2016;31:268\u201385.","journal-title":"Hum Psychopharmacol"},{"key":"1291_CR19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.euroneuro.2011.11.011","volume":"22","author":"E Vieta","year":"2012","unstructured":"Vieta E, Cruz N. Head to head comparisons as an alternative to placebo-controlled trials. Eur Neuropsychopharmacol. 2012;22:800\u20133.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1291_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/JCP.0b13e318033bd5e","volume":"27","author":"DL Zimbroff","year":"2007","unstructured":"Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorders: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007;27:171\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"1291_CR21","unstructured":"Adasuve\u00ae 9.1 mg inhalation powder. Summary of Product Characteristics. Alexza UK Ltd. 20 February 2013."},{"key":"1291_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","volume":"188","author":"R Andrezina","year":"2006","unstructured":"Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo controlled comparison with intramuscular haloperidol. Psychopharmacology. 2006;188:281\u201392.","journal-title":"Psychopharmacology"},{"key":"1291_CR23","first-page":"76","volume-title":"Clinical global impressions (CGI) ECDEU assessment Manual for psychopharmacology, US Department of Health Education, and welfare publication (ADM)","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impressions (CGI) ECDEU assessment Manual for psychopharmacology, US Department of Health Education, and welfare publication (ADM); 1976. p. 76\u2013338."},{"key":"1291_CR24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction Questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"1291_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/0091270009347866","volume":"50","author":"DA Spyker","year":"2010","unstructured":"Spyker DA, Munzar P, Cassella J. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50:169\u201379.","journal-title":"J Clin Pharmacol"},{"key":"1291_CR26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4088\/JCP.10m06011yel","volume":"72","author":"MH Allen","year":"2011","unstructured":"Allen MH, Felfel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:1313\u201321.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"1291_CR27","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Steven D, Targum MD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"1291_CR28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-9-18","volume":"9","author":"A Montoya","year":"2011","unstructured":"Montoya A, Valladares A, Lizan L, et al. Validation of the excited component of the positive and negative syndrome scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9:18.","journal-title":"Health Qual Life Outcomes"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-017-1291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T14:10:07Z","timestamp":1498399807000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-017-1291-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1186\/s12888-017-1291-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]},"article-number":"126"}}